Seeking Alpha
View as an RSS Feed

KarinCA  

View KarinCA's Comments BY TICKER:
Latest  |  Highest rated
  • Interview With Dr Christopher Missling, CEO Of Anavex [View article]
    That's a good find.

    " Dr V. did refuse to sign, it seems - and for obvious reasons - but his signature isn't required per 35 U.S.C. § 262. "

    It will be fascinating to watch this one play out. I picked some shares up after the pr a few days ago. ;)
    Jul 24, 2015. 01:33 PM | Likes Like |Link to Comment
  • Cellceutix Undervalued By 90+%; Expect A Short Squeeze Soon [View article]
    $CTIX - Cellceutix to Start Brilacidin Phase 3 Program in ABSSSI
    http://bit.ly/1ebMfcp
    Jul 20, 2015. 11:43 AM | 2 Likes Like |Link to Comment
  • Cellceutix's Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer [View article]
    Orphan drug status for Kevetrin is excellent news. Especially, since the phase I safety trial isn't ended yet! ;)

    http://1.usa.gov/1V4mmwJ

    All of their trials can be found here: http://1.usa.gov/1CCGluY
    Jul 15, 2015. 04:08 PM | Likes Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    $CTIX - Kevetrin Receives FDA Orphan Drug Designation for the Treatment of Ovarian Cancer
    http://bit.ly/1V3V2yA
    Jul 15, 2015. 01:52 PM | Likes Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    $CTIX added a 5th clinical trial: http://1.usa.gov/1CCGluY
    Jul 10, 2015. 11:05 AM | Likes Like |Link to Comment
  • Cellceutix's Fundamental Strength Outweighs Market Cap [View article]
    Small Pharma Analyst.... Blood pressure events low in 0.6 mg/kg single-dose regimen, similar to or better than daptomycin. It will be interesting to see the dosages used in the Brilacidin phase 3.
    Jun 23, 2015. 07:52 AM | 1 Like Like |Link to Comment
  • Cellceutix's Fundamental Strength Outweighs Market Cap [View article]
    $CTIX Corporate fact sheet June 2015:
    http://bit.ly/1H7jLfB
    Jun 22, 2015. 01:19 PM | 2 Likes Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    $CTIX Corporate fact sheet June 2015:
    http://bit.ly/1H7jLfB
    Jun 22, 2015. 01:15 PM | Likes Like |Link to Comment
  • Obama heads to Nike HQ for TPP pitch [View news story]
    What's 10,000 or up to 40,000 new jobs in US when NIKE employs over 1,000,000 indirectly in Asia. Time to focus on a company employing a majority of US workers.

    I'd buy cheap shoes and put expensive orthotics in them before giving NIKE a dime.

    NKE is bad for the US. Too many jobs are drained away and they think 10,000 new ones in US makes up for it? lol I really dislike their labor practices.
    May 9, 2015. 07:27 PM | 2 Likes Like |Link to Comment
  • Interview With Leo Ehrlich, Cellceutix CEO Following Acquisition Of PolyMedix Assets [View article]
    Follow up on assets since acquisition:

    A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
    http://bit.ly/1DDFuGJ

    ECCMID 2015 Copenhagen, Denmark 25 – 28 April 2015

    Synthetic Novel Host Defense Protein Mimetics for the Treatment of Gram-Negative Bacterial Infections
    http://bit.ly/1z6Dha9

    ECMIID 2015 Copenhagen, Denmark 25 – 28 April 2015

    Brilacidin, Host Defence Peptide mimetic, one of a new class of immunomodulatory ECCMD-0268 agents that can target multiple disease indications
    http://bit.ly/1DDFvum

    2015 ECCMID Copenhagen, Denmark
    Apr 27, 2015. 02:49 PM | Likes Like |Link to Comment
  • Update: Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol [View article]
    A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections (ABSSSI)
    http://bit.ly/1DDFuGJ

    ECCMID 2015 Copenhagen, Denmark 25 – 28 April 2015


    Synthetic Novel Host Defense Protein Mimetics for the Treatment of Gram-Negative Bacterial Infections
    http://bit.ly/1z6Dha9

    ECMIID 2015 Copenhagen, Denmark 25 – 28 April 2015


    Brilacidin, Host Defence Peptide mimetic, one of a new class of immunomodulatory ECCMD-0268 agents that can target multiple disease indications
    http://bit.ly/1DDFvum

    2015 ECCMID Copenhagen, Denmark
    Apr 27, 2015. 02:11 PM | Likes Like |Link to Comment
  • Tekmira's Ebola vaccine candidate cleared for repeat dosing in Phase 1 study [View news story]
    It's not a vaccine. The Tekmira press release doesn't have the word vaccine in it since it's a therapeutic.

    http://bit.ly/1b5tcjg

    "the partial clinical hold on the company's Investigational New Drug application (IND) for TKM-Ebola has been modified to permit repeat dosing of healthy volunteers at a dose of 0.24 mg/kg/day. The IND remains on partial clinical hold with regard to doses above 0.24 mg/kg/day in healthy volunteers.

    Tekmira plans to resume the TKM-Ebola Phase I clinical trial in the coming weeks. The study is a randomized, single-blind, placebo-controlled study involving repeat dosing of a single cohort of healthy volunteers. Each subject will receive daily doses of 0.24mg/kg of TKM-Ebola or placebo for up to seven days. TKM-Ebola will be administered without steroid pre-medication. Results from the study are expected in the second half of 2015."

    The trial that was authorized to start in Africa on sick patients is a separate issue. I wonder how many patients they've been able to enroll since the epidemic has been subsiding?

    http://bit.ly/1b5teaN

    "TKM-Ebola-Guinea will be evaluated for efficacy in Ebola virus infected patients in Sierra Leone, West Africa. Patient recruitment has been initiated. Patient recruitment has been initiated."
    Apr 16, 2015. 04:01 AM | Likes Like |Link to Comment
  • An Interview With Cellceutix CEO Leo Ehrlich [View article]
    Cellceutix Meeting With FDA to Discuss Phase 2 Clinical Trial for Ulcerative Proctitis Treatment;

    Cellceutix’s Abstract on Kevetrin to Be Presented at ASCO -

    See more at: http://bit.ly/1C8unDH
    Apr 1, 2015. 11:59 AM | Likes Like |Link to Comment
  • Advanced Cell Technology's Intellectual Property Takes A Hit [View article]
    DWD Investing... the following cited work from the first sentence of this article has been discredited:

    Nature article:
    http://bit.ly/1HehbSB

    Scientist Resigns as Stem-Cell Creation Method Is Discredited
    http://bit.ly/1HehcWF

    I'm thinking this article may have been written before the Obokata work was discredited.
    Mar 29, 2015. 08:45 PM | 1 Like Like |Link to Comment
  • Should You Cancel Your Phone, TV And Internet Service Contracts? [View article]
    Elliott... I don't bother going to stores unless I need to physically try something on. There have been times I'll buy two pairs of shoes if unsure of the size and simply return the pair that doesn't fit. I only do this if in a hurry.

    90% of my shopping is done online with the vast majority of it from Amazon. With Amazon prime I get free shipping and most of Amazon prime entertainment for free. All for $99 annually. It's impossible to watch all available to me via Netflix, Amazon Prime and Youtube. The savings is unbelievable. My cost for the setup is a onetime fee for the hotspot app $7.95, Amazon Prime onetime fee of $99, and $8 monthly for Netflix. My Amazon Prime fee has been returned many times over due to the free shipping it gives me. I get daily packages and if I agree to one week shipping instead of 2 day they give me $1 credit in my account.

    I'm looking at a farmer that delivers boxes of vegetables once a week to try and eliminate the grocery store.

    I know many that pay the cell phone company a monthly fee for hotspot usage, but, that's not even needed with an app.

    Just make sure your smart phone is at least 4g for everything to work right. ;)
    Mar 16, 2015. 06:04 PM | 1 Like Like |Link to Comment
COMMENTS STATS
426 Comments
716 Likes